Cross trial
Asking for Preferences
Cross trial for oesophageal carcinoma
Reading File
Searching PubMed
CROSS trial oesophageal carcinoma neoadjuvant chemoradiotherapy
Searching the Web
CROSS trial oesophageal cancer neoadjuvant chemoradiotherapy carboplatin paclitaxel results
Finding Sources
Reading Article
PMID: 26254683
Reading Article
PMID: 22646630
Reading File
I have comprehensive data. Let me now compile the full detailed answer.
The CROSS Trial - Oesophageal Carcinoma
What is the CROSS Trial?
CROSS stands for ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study. It is the landmark phase III randomised controlled trial that established neoadjuvant chemoradiotherapy (nCRT) as a standard of care for resectable oesophageal and oesophagogastric junction (OGJ) cancer.
Background
Prior to CROSS, the role of neoadjuvant therapy was unclear. Small, underpowered trials had used inconsistent dosing and fractionation. The CROSS trial defined a new benchmark across oesophageal oncology. Published initially in the NEJM (2012) by van Hagen et al., with long-term follow-up reported in Lancet Oncology (2015) by Shapiro et al.
Study Design
| Parameter | Detail |
|---|---|
| Design | Phase III multicentre RCT (8 Dutch centres) |
| Enrolment | March 2004 - December 2008 |
| n | 368 enrolled; 366 analysed |
| Randomisation | 1:1 - nCRT + Surgery vs. Surgery alone |
| Eligible stages | T1N1M0 or T2-3N0-1M0 (TNM 6th ed.) - clinically resectable |
| Histology | Adenocarcinoma 75%, SCC 23%, Large-cell undifferentiated 2% |
Treatment Regimen
Experimental Arm: Neoadjuvant CRT + Surgery
Chemotherapy (weekly x 5 cycles):
- Carboplatin: AUC 2 mg/mL/min IV (Days 1, 8, 15, 22, 29)
- Paclitaxel: 50 mg/m² IV (Days 1, 8, 15, 22, 29)
Concurrent Radiotherapy:
- Total dose: 41.4 Gy in 23 fractions of 1.8 Gy each, 5 days/week
Then: Surgery (oesophagectomy)
Control Arm: Surgery alone
Key Results
Primary Endpoint - Overall Survival
| Outcome | nCRT + Surgery | Surgery Alone | HR | p-value |
|---|---|---|---|---|
| Median OS (initial NEJM 2012) | 49.4 months | 24.0 months | 0.657 | 0.003 |
| Median OS (long-term Lancet Oncol 2015) | 48.6 months | 24.0 months | 0.68 (0.53-0.88) | 0.003 |
| 5-year OS | ~47% | ~34% | - | - |
By Histological Subtype (Long-term data)
| Subtype | nCRT + Surgery (Median OS) | Surgery Alone (Median OS) | HR | p |
|---|---|---|---|---|
| Squamous cell carcinoma | 81.6 months | 21.1 months | 0.48 (0.28-0.83) | 0.008 |
| Adenocarcinoma | 43.2 months | 27.1 months | 0.73 (0.52-0.99) | 0.049 |
SCC benefited far more than adenocarcinoma, reflecting different tumour biology and greater radiosensitivity.
Secondary Endpoints
| Endpoint | nCRT + Surgery | Surgery Alone | p |
|---|---|---|---|
| R0 resection rate | 92% | 69% | <0.001 |
| Pathological complete response (pCR) | 29% (47/161) | N/A | - |
| In-hospital mortality | 4% | 4% | NS |
- pCR rate for SCC: ~49%
- pCR rate for adenocarcinoma: ~23%
- 95% of patients in the nCRT arm completed the full regimen
Recurrence Patterns (Oppedijk et al., JCO 2014, PMID 24419108)
- nCRT significantly reduced locoregional recurrence (from ~35% to ~14%)
- Also reduced peritoneal dissemination
- Distant metastasis remained an issue in both groups, particularly for adenocarcinoma
Toxicity
Relatively well-tolerated:
- Major haematologic: Leukopenia (6%), neutropenia (2%)
- Major non-haematologic: Anorexia (5%), fatigue (3%)
- Postoperative complications similar between groups
Clinical Impact & Legacy
The CROSS regimen became the global standard of care for resectable locally advanced oesophageal cancer. It is referenced as a Grade A recommendation in Goldman-Cecil Medicine, Current Surgical Therapy, and Sabiston's Surgery.
Subsequent trials building on CROSS:
- ESOPEC trial (PMID 27435280) - compared CROSS vs. perioperative FLOT for oesophageal adenocarcinoma; FLOT showed superior OS for adenocarcinoma, leading to a shift toward FLOT for EAC in some guidelines
- Neo-AEGIS trial - CROSS vs. MAGIC/FLOT chemotherapy for OGJ adenocarcinoma
- 10-year follow-up (CROSS Study Group, 2021) - confirmed durable long-term survival benefit
Summary
The CROSS trial demonstrated that neoadjuvant carboplatin/paclitaxel with 41.4 Gy concurrent radiotherapy followed by surgery, compared to surgery alone:
- Doubled median overall survival (48.6 vs. 24 months)
- Dramatically improved R0 resection rates (92% vs. 69%)
- Achieved ~29% pathological complete response
- Was particularly effective in SCC (median OS 81.6 months)
- Had acceptable, manageable toxicity
This trial is the cornerstone of multimodal oesophageal cancer management and continues to define standard-of-care practice globally.
Sources: van Hagen et al., NEJM 2012 (PMID 22646630) | Shapiro et al., Lancet Oncol 2015 (PMID 26254683) | Current Surgical Therapy 14e | Goldman-Cecil Medicine
Pdf download
I'd love to help, but PDF full-text download is not available in this session - the
pubmed_fulltext tool has 0 uses allocated in the current budget.Here are the best ways to access the CROSS trial papers directly:
Original CROSS Trial (NEJM 2012)
- PMID: 22646630
- Free access via: nejm.org/doi/full/10.1056/NEJMoa1112088
Long-term Results (Lancet Oncology 2015)
- PMID: 26254683
- Access via: pubmed.ncbi.nlm.nih.gov/26254683
- May require institutional login; also available via Sci-Hub or your hospital/university library portal
Recurrence Patterns Paper (JCO 2014)
- PMID: 24419108
- Access via: pubmed.ncbi.nlm.nih.gov/24419108
Quick Options
- PubMed Central (PMC) - search the PMID; some may have free PMC full text
- ResearchGate - authors often self-upload their papers
- Unpaywall browser extension - automatically finds free legal versions of papers
Would you like me to generate a structured PDF summary of the CROSS trial based on the data I already retrieved? I can create a downloadable PDF document with all the key details, tables, and results.
Download original paper
Unfortunately, the pubmed_fulltext tool has 0 uses allocated in this session's budget, so I cannot download the paper directly.
How to Get the Original Paper
Option 1 - Free Legal Access (NEJM 2012 - van Hagen et al.)
The original CROSS trial was published in NEJM and is freely accessible:
Option 2 - PubMed Entry
Option 3 - Long-term Results (Lancet Oncol 2015)
Alternative: Downloadable Summary PDF
I can create a well-formatted PDF summary of the CROSS trial using all the data already retrieved - covering background, design, regimen, results tables, recurrence data, and clinical significance. This would be ready to download instantly.
Would you like me to do that?
This is a shared conversation. Sign in to Orris to start your own chat.